WIPO trademark

BIPERXAM

MixedWIPOClass 5

"BIPERXAM" is a trademark owned by Biofarma, filed at the WIPO on November 28, 2025. It is on file and covers class 5 (Pharmaceuticals).

BIPERXAM
Trademark as filed with the WIPO
Status
Mixed
Filed
November 28, 2025
Registered
Not yet
Expires
November 28, 2035
Application no.
Not recorded
Registration no.
1895510
Office
WIPO
World Intellectual Property Organization
Mark type
Trademark
1 class
Ownership

Who owns BIPERXAM

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Goods and services

What the mark covers

The products and services BIPERXAM is filed for, grouped by Nice class.

  • Cardiovascular pharmaceutical products; pharmaceutical products for prevention of diseases of the metabolic system; pharmaceutical products for treatment of diseases of the metabolic system.

FAQ

About BIPERXAM

Who owns the trademark "BIPERXAM"?

The WIPO trademark "BIPERXAM" is owned by Biofarma.

What is the status of "BIPERXAM"?

Its status at the WIPO is: mixed.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull BIPERXAM and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

GET /v1/trademarks/{id}
ID=tm_838da2d2-b4bc-4930-b3d3-90b7a4aaed31
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_838da2d2-b4bc-4930-b3d3-90b7a4aaed31",
  "object": "trademark",
  "mark_text": "BIPERXAM",
  "status": {
    "primary": "mixed",
    "stage": "mixed"
  },
  "office_code": "WO",
  "application_number": null,
  "filing_date": "2025-11-28",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "BIOFARMA",
      "entity_id": "ent_019eb7a4-801f-7200-9074-3a8d4e459b8b"
    }
  ]
}